Barely Significant
← all excerpts

Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma.

Front Immunol · 2023 · PMC9909478 · PMID 36776886

Europe PMCDOI
1
hedged sentence
0.0421
closest p · 0.8× alpha
0.0421
boldest claim

The sentences

failed to achieve significancep = 0.0421actually significant
Despite this, the recently published final results of the ORACLE phase III study comparing oral 5-azacytidine to investigator’s choice in R/R AITL failed to achieve significance in the primary endpoint of PFS with a median PFS in the 5-azacytidine group of 5.6 months versus 2.8 months in the standard arm (p = 0.0421) ( 140 ).

also in 299 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.